Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 4/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294443 | 0.87 | NPC1 (0.41) | TARBP2MAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL23294607 | 0.86 | MAPT (0.41) | TARBP2MAPTCYP19A1CA9CA1 | |
| SCHEMBL26849528 | 0.85 | MAPT (0.42) | TARBP2MAPTCYP19A1RAB9ASMN1; SMN2 | |
| SCHEMBL23294586 | 0.84 | GABRG2 (0.40) | TARBP2MAPTCYP19A1CA9CA1 | |
| SCHEMBL29852224 | 0.84 | GABRG2 (0.40) | TARBP2MAPTCYP19A1CA9CA1 | |
| SCHEMBL23294656 | 0.83 | LIPG (0.36) | TARBP2MAPTCA9CA1CA2 | |
| SCHEMBL23294312 | 0.83 | ALDH1A1 (0.34) | TARBP2MAPTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL23294459 | 0.82 | TARBP2 (0.40) | TARBP2MAPTCYP19A1HTTCA9 | |
| SCHEMBL23294560 | 0.82 | KMT2A (0.44) | MAPTCYP19A1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL23294581 | 0.81 | UCHL1 (0.36) | TARBP2MAPTCA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| CN-114929676-B | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | LILAC THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4470538-A2 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4051667-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20210128532-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
| WO-2021086874-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | GyanRx Sciences, Inc. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | TARBP2 4367/4885MAPT 3488/4885CYP19A1 1204/4885 |
| US-20210128532-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | UGDH, PGD, PNPO | TARBP2 4367/4885MAPT 3488/4885CYP19A1 1204/4885 |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | GLS, DUOX1, HAO1 | TARBP2 4610/4885MAPT 3882/4885CYP19A1 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.